BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 10681415)

  • 1. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
    J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
    Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
    J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
    Taskinen MR; Packard CJ; Shepherd J
    Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.
    Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
    Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1726-32. PubMed ID: 12377756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
    Hooper AJ; Heeks L; Robertson K; Champain D; Hua J; Song S; Parhofer KG; Barrett PH; van Bockxmeer FM; Burnett JR
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1484-90. PubMed ID: 26323024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles.
    Lundahl B; Skoglund-Andersson C; Caslake M; Bedford D; Stewart P; Hamsten A; Packard CJ; Karpe F
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E739-45. PubMed ID: 16291571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
    Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
    Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
    Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH
    Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.